An increasing number of studies have identified signal pathway and gene abnormalities in PTCL, such as the NF-κB and mTOR pathways, and the IDH and TET2 mutations. This evidence concerns the gene NFKB1 and mature T-cell and NK-cell non-Hodgkin lymphoma.